FY2025 Earnings Forecast for CRSP Issued By Chardan Capital

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Chardan Capital lifted their FY2025 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($4.60) per share for the year, up from their previous estimate of ($4.62). Chardan Capital currently has a "Buy" rating and a $82.00 price target on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The company's revenue for the quarter was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.43) EPS.

Several other equities analysts have also recently weighed in on the stock. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, March 21st. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Stifel Nicolaus cut their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a report on Thursday, February 13th. TD Cowen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target for the company in a report on Wednesday, February 12th. Finally, Needham & Company LLC lowered their price objective on CRISPR Therapeutics from $84.00 to $81.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Price Performance

Shares of CRSP traded up $1.28 during mid-day trading on Monday, hitting $37.59. 890,247 shares of the company's stock were exchanged, compared to its average volume of 1,667,065. The company has a market cap of $3.25 billion, a PE ratio of -8.64 and a beta of 1.88. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $67.88. The company has a 50-day simple moving average of $37.57 and a 200 day simple moving average of $42.46.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This trade represents a 9.66% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is currently owned by insiders.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Magnetar Financial LLC purchased a new stake in CRISPR Therapeutics during the fourth quarter valued at $359,000. Baker BROS. Advisors LP increased its position in CRISPR Therapeutics by 55.1% during the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after acquiring an additional 464,936 shares during the last quarter. Vanguard Group Inc. increased its position in CRISPR Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after acquiring an additional 10,579 shares during the last quarter. KBC Group NV increased its position in CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in CRISPR Therapeutics during the fourth quarter valued at about $3,231,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.